Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 12/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 11/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.72 |
| ▸ | LMNA | P02545 | 9/20 | 0.72 |
| ▸ | USP2 | O75604 | 9/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.72 |
| ▸ | EGFR | P00533 | 6/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 7/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29133772 | 0.89 | CYP1A2 (0.57) | CLK4ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30301815 | 0.84 | CLK4 (1.00) | CLK4ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24576556 | 0.82 | EGFR (0.68) | CLK4ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24576768 | 0.82 | EGFR (0.72) | CLK4ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30301817 | 0.80 | EGFR (1.00) | CLK4ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17845967 | 0.80 | EGFR (1.00) | CLK4ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24576823 | 0.78 | EGFR (0.64) | CYP1A2CYP3A4LMNAMAPK1HIF1A | |
| SCHEMBL1675019 | 0.77 | CLK4 (1.00) | CLK4ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1675082 | 0.75 | CLK4 (1.00) | CLK4ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17845927 | 0.75 | LMNA (1.00) | CLK4ALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3233085-B1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF EGFR AND PI3K | UNIV MICHIGAN REGENTS (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| EP-3955923-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | The Regents Of The University Of Michigan (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-113354617-A | Small molecule inhibitors of EGFR and PI3K | 密歇根大学董事会 | 2021-09-07 | — | — | CN | disclosed |
| CN-107531665-B | Small molecule inhibitors of EGFR and PI3K | 密歇根大学董事会 | 2021-03-30 | — | — | CN | disclosed |
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-01-28 | — | — | US | disclosed |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020215037-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| EP-3233085-A2 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | The Regents of The University of Michigan (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100347-A2 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | CLK4 460/4885ALDH1A1 4653/4885CYP1A2 2730/4885 |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | CLK4 460/4885ALDH1A1 4653/4885CYP1A2 2730/4885 |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | CLK4 460/4885ALDH1A1 4653/4885CYP1A2 2730/4885 |
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | CLK4 460/4885ALDH1A1 4653/4885CYP1A2 2730/4885 |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | CLK4 460/4885ALDH1A1 4653/4885CYP1A2 2730/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | CLK4 460/4885ALDH1A1 4653/4885CYP1A2 2730/4885 |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | CD274, PDCD1, PDCD1LG2 | CLK4 1132/4885ALDH1A1 608/4885CYP1A2 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.